Due to the lack of CMTM6-targeting chemicals, HuR inhibitors therefore may serve as an alternative to indirectly suppress PD-L1 expression and synergistically circumvent tumor immune escape in combination with PD-1/PD-L1 antibodies. This evidence concerns the gene ELAVL1 and neoplasm.